Journal of palliative medicine
Gefapixant Citrate, a Selective P2X3 Receptor Antagonist, May Improve Cancer-Related Hypergeusia: A Case Report.
Satoshi Murakami, Kazutaka Yamagishi, Akira Kitani, Toru Ueta, Yasuaki Matsuura, Toru Kubota, Yasuhito Uezono
Published: 202510.1177/10966218251385732
Abstract
Patients with cancer frequently experience taste disorders that substantially affect their quality of life. Gefapixant citrate, a P2X purinoceptor 3 receptor antagonist, is an antitussive agent known to cause taste-related adverse effects. In this st…
Preview only. Read the full abstract at the source